XOMA again on a PhII failure. About 35%.
XOMA Ltd. (XOMA) After Hours Trading
Mar. 22, 2011 Market Close: $ 5.02
After Hours Last: $ 3.23
Net / % Change -1.79 (-35.66%)
After Hours High: $ 5.01
After Hours Volume: 497,181
After Hours Low: $ 3.10
4:21PM XOMA Limited announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint (XOMA) 5.02 +0.28 : Co announced that its Phase 2b trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo. Biological activity of XOMA 052 supporting its potential in cardiovascular disease was observed with highly significant (p < or = 0.0005) decreases in C-reactive protein, or CRP, a biomarker for the risk of heart attack, stroke and other cardiovascular diseases, in all dose groups versus placebo. In addition, statistically significant improvements in high-density lipoprotein, or "good" cholesterol were observed in two of four XOMA 052 dose groups versus placebo. XOMA 052 was well-tolerated in this trial, with no serious drug-related adverse events and a safety profile consistent with previous trials. XOMA is developing XOMA 052 in collaboration with Servier. |
